New Jersey, United States: Market Research Intellect has added a new research report titled, Human Embryonic Stem Cells (HESC) Market Professional Survey Report 2020 to its vast collection of research reports. The Human Embryonic Stem Cells (HESC) market is expected to grow positively for the next five years 2020-2026. The Human Embryonic Stem Cells (HESC) market report studies past factors that helped the market to grow as well as, the ones hampering the market potential
The report titled Global Cell Freezing Media for Cell Therapy Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cell Freezing Media for Cell Therapy market
Just when you thought the world couldnt get any spookier, say hello to the newly born xenobot, a new kind of living thing. Its hard to say with certainty who the father is. Or maybe its just hard to admit whats actually happened: Like a bright child making a weirdo companion from Play-Doh, artificial intelligence has mated with the living cells of a frog to create an eerie hybrid of life and machine.
The hydra, a tiny sea creature, appears to never age. Scientists are studying it to learn what secrets it may hold to longevity. Leonardo Santamaria for NPR A stint as lion tamer in Hollywood got Steven Austad interested in animal biology
Embryonic Stem Cells Definition An embryonic stem cell is a cell derived from the early stages of an embryo which is capable of differentiating into any type of body cell. Embryonic stem cells are capable of differentiating into any cell type because in the embryo that is what they are used for. As the embryo grows and divides, cells which are generalized must become more and more specific as they divide.
SUZHOU, Chinaand SHANGHAI, Jan. 7, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed using TruUCAR to treat relapsed or refractory (R/R) T-cell malignancies.
Gene-editing technologies have huge potential to alleviate human suffering. But, like all very powerful technologies, they also carry enormous risks if used improperly.
After years of ethical debates and breakthroughs in the lab, CRISPR has finally made its way to clinical trials. Researchers are now looking at whether the DNA-editing tool, as well as more conventional gene therapies, can effectively treat a wide array of heritable disorders and even cancers. Theres been a convergence of the science getting better, the manufacturing getting much better, and money being available for these kinds of studies, says Cynthia Dunbar, a senior investigator at the National Heart, Lung, and Blood Institute
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-604 trial investigating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) in the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC). In the study, treatment with KEYTRUDA in combination with chemotherapy (etoposide plus cisplatin or carboplatin) resulted in a statistically significant improvement in PFS compared to chemotherapy alone (HR=0.75 [95% CI, 0.61-0.91]), which was observed at a prior interim analysis
The city is set to host the fifth edition of the Asia Pacific Drosophila Research Conference (APDRC5), which is being organised in the country for the first time by the Indian Institute of Science Education and Research (IISER). This biennial conference, which is to be held between January 6 and 10, aims to promote the interaction of Drosophila researchers in the Asia-Pacific region with their peers in the rest of the world.
Recent Comments